Nimodipine microparticles - Edge Therapeutics

Drug Profile

Nimodipine microparticles - Edge Therapeutics

Alternative Names: EG-1962; NimoVent; Polymeric nimodipine microparticle

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator Edge Therapeutics
  • Class Antihypertensives; Dihydropyridines; Nicotinic-acids
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Subarachnoid haemorrhage
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Cerebral ischaemia
  • New Molecular Entity No
  • Available For Licensing Yes - Brain injuries; Cerebral ischaemia

Highest Development Phases

  • Phase III Cerebral ischaemia

Most Recent Events

  • 01 Nov 2016 Phase-I clinical trials in Cerebral ischaemia (Prevention) in USA (Intracisternal) (NCT02893826)
  • 06 Sep 2016 Pharmacokinetics data from the phase I/IIa trial in Cerebral ischaemia (Prevention) released by Edge Therapeutics
  • 03 Aug 2016 Edge Therapeutics has patent protection for nimodipine microparticles in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top